Lupin signs marketing agreement with Forest Laboratories

Under the terms of the agreement, Lupin Pharmaceuticals, USA, will use its 50 person sales force to promote the product to pediatricians.

This agreement with Forest Laboratories is said to reflect Lupin’s commitment to bring value additions to the US market to improve the overall health of the patient population. This alliance will also extend Lupin’s presence in the respiratory segment and help strengthen its franchise with pediatricians.

AeroChamber Plus is a valved holding chamber device that is used with metered dose inhalers to improve the delivery of medication to the lungs in the treatment of asthma and chronic obstructive pulmonary disease.

Vinita Gupta, president of Lupin Pharmaceuticals, said: “We are happy to strike this alliance with Forest. While the AeroChamber Plus brand has a strong position in the valved holding chamber market, we believe that this marketing alliance presents a significant opportunity for further growth of the franchise for Forest, resulting in value for both companies.”